NVAX:NASDAQ
Novavax Inc
US$ 12,50
arrow_downward
-1,97%(-0,25) 1D
12 okt, 15:09:47 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor NVAX genereren…
Openen
US$ 12,61
Hoog
US$ 12,96
Laag
US$ 12,19
Beursw.
2,06 mld.
Gem. vol.
7,28 mln.
Volume
6,73 mln.
52 wk hoog
US$ 13,38
52 wk laag
US$ 6,20
WPA
US$ -1,52
Bèta
2,44
Uitstaande aandelen
164,95 mln.
Aantal medewerkers
749
Openen
US$ 12,61
Hoog
US$ 12,96
Laag
US$ 12,19
Beursw.
2,06 mld.
Gem. vol.
7,28 mln.
Volume
6,73 mln.
52 wk hoog
US$ 13,38
52 wk laag
US$ 6,20
WPA
US$ -1,52
Bèta
2,44
Uitstaande aandelen
164,95 mln.
Aantal medewerkers
749
Nieuwsartikelen
Van webbronnen en nieuwspartners
Zacks
·
4 uur geleden
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Benzinga
·
10 uur geleden
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Simply Wall Street
·
1 dag geleden
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
24/7 Wall St.
·
3 dagen geleden
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Profiel
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Over Novavax Inc
CEOJohn C. Jacobs
Medewerkers749
Opgericht1987
HoofdkantoorGaithersburg, Maryland, Verenigde Staten
Sector-
Websitenovavax.com